title: [BEP (bleomycin, etoposide, cisplatinum) chemotherapy as an induction therapy of advanced extragonadal germ cell tumor].
abstract: Five patients with advanced extragonadal germ cell tumor (EGGCT) were treated with cisplatinum + vinblastine + bleomycin (BVP) or cisplatinum + etoposide + bleomycin (BEP) chemotherapy as an induction therapy. All patients had high levels of tumor markers and multiple distant metastasis in poor nutritious conditions. Two patients given BVP therapy died 6 and 9 months after the chemotherapy. By contrast, three patients given BEP therapy achieved complete remission and were surviving longer than one year without any evidences of disease. Granulocytopenic fever was seen soon after the first course of BEP therapy. Prophylactic granulocyte-colony stimulating factor (G-CSF) treatment, enabled two of them to receive full dose chemotherapy without any fever attacks. In conclusion, BEP chemotherapy is effective to EGGCT as well as far advanced testicular tumors and G-CSF treatment is useful for achievement of induction chemotherapy to advanced germ cell tumors.
authors.affiliation: Department of Urology, Tokyo Medical and Dental University School of Medicine.
authors.forename: S
authors.initials: S
authors.lastname: Goto
authors.forename: I
authors.initials: I
authors.lastname: Fukui
authors.forename: M
authors.initials: M
authors.lastname: Ando
authors.forename: K
authors.initials: K
authors.lastname: Kihara
authors.forename: S
authors.initials: S
authors.lastname: Kitahara
authors.forename: T
authors.initials: T
authors.lastname: Tsujii
authors.forename: A
authors.initials: A
authors.lastname: Noro
authors.forename: T
authors.initials: T
authors.lastname: Hagiwara
authors.forename: T
authors.initials: T
authors.lastname: Toyoshima
authors.forename: T
authors.initials: T
authors.lastname: Tsukamoto
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy*; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000556:secondary / Q000628:therapy*; D012074:Remission Induction; D012186:Retroperitoneal Neoplasms / Q000473:pathology / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor; D001761:Bleomycin; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D002945:Cisplatin